Transcenta, a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, R&D, regulatory affairs and manufacturing, has achieved a major milestone in its continuous perfusion cell culture platform by achieving volumetric productivities of > 4 g/L per day for multiple cell lines expressing monoclonal antibodies.     This is a significant milestone and Transcenta achieved this using in-house developed chemically-defined media, robust cell line expression ...